"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 20 | 20 |
| 1994 | 0 | 23 | 23 |
| 1995 | 0 | 29 | 29 |
| 1996 | 0 | 33 | 33 |
| 1997 | 0 | 34 | 34 |
| 1998 | 0 | 34 | 34 |
| 1999 | 0 | 36 | 36 |
| 2000 | 0 | 31 | 31 |
| 2001 | 0 | 44 | 44 |
| 2002 | 0 | 36 | 36 |
| 2003 | 0 | 46 | 46 |
| 2004 | 0 | 41 | 41 |
| 2005 | 0 | 50 | 50 |
| 2006 | 0 | 52 | 52 |
| 2007 | 0 | 61 | 61 |
| 2008 | 0 | 58 | 58 |
| 2009 | 0 | 51 | 51 |
| 2010 | 0 | 43 | 43 |
| 2011 | 0 | 68 | 68 |
| 2012 | 0 | 64 | 64 |
| 2013 | 0 | 60 | 60 |
| 2014 | 0 | 61 | 61 |
| 2015 | 0 | 51 | 51 |
| 2016 | 0 | 57 | 57 |
| 2017 | 0 | 51 | 51 |
| 2018 | 0 | 60 | 60 |
| 2019 | 0 | 61 | 61 |
| 2020 | 0 | 57 | 57 |
| 2021 | 0 | 50 | 50 |
| 2022 | 0 | 32 | 32 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 02; 9(2):183-191.
-
Roflumilast May Increase Risk of Exacerbations When Used to Treat Poorly Controlled Asthma in People with Obesity. Ann Am Thorac Soc. 2023 02; 20(2):206-214.
-
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother. 2022 12 15; 9(1):85-93.
-
Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol. 2022 12; 17(12):1763-1774.
-
Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy. 2022 11; 14(16):1279-1290.
-
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 12 03; 400(10367):1927-1937.
-
A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206.
-
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology. 2023 01; 48(2):418-426.
-
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial. J Bone Miner Res. 2022 12; 37(12):2435-2442.
-
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension. 2022 12; 79(12):2685-2695.